Kan et al. [36] investigated the effects of alogliptin treatment on liver function and glucose metabolism in NAFLD patients with T2D, carrying different PNPLA3 rs738409 C > G genotypes. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.